Charles O. Williams Sells 1,181 Shares of Surrozen, Inc. (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) CFO Charles O. Williams sold 1,181 shares of Surrozen stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $17.37, for a total value of $20,513.97. Following the transaction, the chief financial officer now directly owns 8,982 shares in the company, valued at approximately $156,017.34. The trade was a 11.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Surrozen Trading Down 9.0 %

Shares of NASDAQ:SRZN opened at $12.95 on Wednesday. The stock has a fifty day moving average of $11.08 and a 200-day moving average of $9.95. Surrozen, Inc. has a one year low of $6.00 and a one year high of $18.17.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.77) by $2.33. The company had revenue of $10.00 million during the quarter. As a group, equities research analysts anticipate that Surrozen, Inc. will post -7.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Guggenheim raised shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price objective on the stock in a research note on Friday, January 3rd.

Institutional Investors Weigh In On Surrozen

Several hedge funds have recently made changes to their positions in the company. Armistice Capital LLC acquired a new position in Surrozen in the 2nd quarter worth approximately $2,080,000. Nantahala Capital Management LLC acquired a new stake in shares of Surrozen in the second quarter worth $2,050,000. Stonepine Capital Management LLC purchased a new position in shares of Surrozen during the second quarter valued at $724,000. Finally, CVI Holdings LLC purchased a new position in shares of Surrozen during the second quarter valued at $711,000. Hedge funds and other institutional investors own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.